REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

15/05/2024 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240515:nRSO5631Oa&default-theme=true

RNS Number : 5631O  AstraZeneca PLC  15 May 2024

15 May 2024 15:00 BST

 

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announced that on 13 May 2024, Pascal Soriot,
Chief Executive Officer, was granted an award of the Company's ordinary shares
of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Performance
Share Plan (AZPSP), as detailed in the table below.

 

This award forms part of the AZPSP award granted to Mr Soriot on 4 March 2024.
As described in AstraZeneca's 2023 Directors' Remuneration Report, it has been
made in accordance with the Directors' Remuneration Policy and amended rules
of the AZPSP approved by shareholders at the Company's 2024 Annual General
Meeting.

 

 PDMR           Ordinary Shares granted under the AZPSP  Award price per Ordinary Share
 Pascal Soriot  29,474                                   £100.81

 

The AZPSP award is subject to a combination of performance measures focused on
scientific, commercial, financial and sustainability performance. The
performance measures will be assessed over a three-year performance period (1
January 2024 to 31 December 2026). The Ordinary Shares granted under the AZPSP
are subject to a two-year holding period following the performance period, and
are due to vest on the fifth anniversary of grant.

 

Details of the performance measures attached to the AZPSP award can be found
in the Directors' Remuneration Report within the AstraZeneca Annual Report and
Form 20-F Information 2023, which is available on the Company's website at
www.astrazeneca.com/annualreport202
(http://www.astrazeneca.com/annualreport2023) 3.

 

Further details are set out in the attached notification, made in accordance
with the requirements of the EU Market Abuse Regulation (as it forms part of
UK law pursuant to the European Union (Withdrawal) Act 2018).

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Pascal Soriot

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of US$0.25 each in AstraZeneca PLC

      Identification code

                                                                   GB0009895292

 b)   Nature of the transaction                                    Grants of share awards under the AstraZeneca Performance Share Plan

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   £100.81   29,474
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      13 May 2024

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

13 May 2024

f)

 

Place of the transaction

 

Outside a trading venue

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUVORRSUUVAAR